Patents by Inventor Jianshi Tao

Jianshi Tao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6846625
    Abstract: The invention comprises methods useful within a larger process for identifying compounds and/or designing further compounds with activity to produce a desired phenotype (for example, growth inhibition) in cells whose target cell component is the subject of certain studies to identify such compounds. The invention employs constructed cells comprising a regulable gene encoding a biomolecule which modulates (inhibits or activates) in vivo the function of a target component of the cell which can be an enzyme for example. The process incorporates methods for identifying biomolecules that bind to a chosen target cell component in vitro, methods for identifying biomolecules that also bind to the chosen target and modulate its function intracellularly, causing a phenotypic effect.
    Type: Grant
    Filed: January 8, 1999
    Date of Patent: January 25, 2005
    Assignee: Cubist Pharmaceuticals, Inc.
    Inventors: Francis P. Tally, Jianshi Tao, Philip A. Wendler, Gene Connelly, Paul L. Gallant
  • Publication number: 20040033481
    Abstract: The invention comprises methods useful within a larger process for identifying compounds and/or designing further compounds with activity to produce a desired phenotype (for example, growth inhibition) in cells whose target cell component is the subject of certain studies to identify such compounds. The invention employs constructed cells comprising a regulable gene encoding a biomolecule which modulates (inhibits or activates) in vivo the function of a target component of the cell which can be an enzyme, for example, methionyl-tRNA synthetase of Staphylococcus aureus. The process incorporates methods for identifying biomolecules that bind to a chosen target cell component in vitro, methods for identifying biomolecules that also bind to the chosen target and modulate its function intracellularly, causing a phenotypic effect.
    Type: Application
    Filed: October 22, 2002
    Publication date: February 19, 2004
    Applicant: Cubist Pharmaceuticals, Inc.
    Inventors: Francis P. Tally, Jianshi Tao, Philip A. Wendler, Gene Connelly, Paul L. Gallant
  • Publication number: 20030054537
    Abstract: A system has been constructed which is suitable for tetracycline-inducible gene expression in Gram-positive bacteria such as Staphylococcus aureus and Bacillus subtilis. The replicon/host gene expression system is tightly regulated, can be used in complex as well as minimal media, and can produce a high level of gene expression upon induction, with a variety of gene products. The gene expression system is suitable for production of products toxic to the host cells, and can be used, for example, for the analysis of gene expression and gene products in Gram-positive bacteria, and in a test of the effect of a peptide or polypeptide inhibitor of an S. aureus enzyme on the growth of S. aureus cells in culture or during infection of an animal.
    Type: Application
    Filed: May 17, 2002
    Publication date: March 20, 2003
    Applicant: Cubist Pharmaceuticals, Inc.
    Inventors: Francis P. Tally, Jianshi Tao, Xiaoyu Shen, Jiansu Zhang
  • Patent number: 6475726
    Abstract: The invention comprises methods useful within a larger process for identifying compounds and/or designing further compounds with activity to produce a desired phenotype (for example, growth inhibition) in cells whose target cell component is the subject of certain studies to identify such compounds. The invention employs constructed cells comprising a regulable gene encoding a biomolecule which modulates (inhibits or activates) in vivo the function of a target component of the cell which can be an enzyme, for example, methionyl-tRNA synthetase of Staphylococcus aureus. The process incorporates methods for identifying biomolecules that bind to a chosen target cell component in vitro, methods for identifying biomolecules that also bind to the chosen target and modulate its function intracellularly, causing a phenotypic effect.
    Type: Grant
    Filed: June 25, 1999
    Date of Patent: November 5, 2002
    Assignee: Cubist Pharmaceuticals, Inc.
    Inventors: Francis P. Tally, Jianshi Tao, Philip A. Wendler, Gene Connelly, Paul L. Gallant, Xiaoyu Shen, Jiansu Zhang
  • Patent number: 6436694
    Abstract: A system has been constructed which is suitable for tetracycline-inducible gene expression in Gram-positive bacteria such as Staphylococcus aureus and Bacillus subtilis. The replicon/host gene expression system is tightly regulated, can be used in complex as well as minimal media, and can produce a high level of gene expression upon induction, with a variety of gene products. The gene expression system is suitable for production of products toxic to the host cells, and can be used, for example, for the analysis of gene expression and gene products in Gram-positive bacteria, and in a test of the effect of a peptide or polypeptide inhibitor of an S. aureus enzyme on the growth of S. aureus cells in culture or during infection of an animal.
    Type: Grant
    Filed: April 14, 1999
    Date of Patent: August 20, 2002
    Assignee: Cubist Pharmaceuticals, Inc.
    Inventors: Francis P. Tally, Jianshi Tao, Xiaoyu Shen, Jiansu Zhang
  • Patent number: 6221640
    Abstract: Recombinant nucleic acids which encode aminoacyl-tRNA sythetases of enterococcal origin or portions of such enzymes, have been isolated. These nucleic acids can be used to make expression constructs and transformed host cells for the production of enterococcal aminoacyl-tRNA synthetases. They can also be used in the further isolation of nucleic acids related by DNA sequence similarities, which also encode enterococcal aminoacyl-tRNA synthetases, or portions thereof. A further embodiment of the invention is antisense nucleic acid which can hybridize to the nucleic acid which encodes the aminoacyl-tRNA synthetase of enterococci. The invention also relates to tRNA synthetases such as isolated and/or recombinant enterococcal aminoacyl-tRNA synthetases. Antibodies which bind to these enzymes can be made and can be used in the purification and study of the enzymes.
    Type: Grant
    Filed: May 14, 1997
    Date of Patent: April 24, 2001
    Assignee: Cubist Pharmaceuticals, Inc.
    Inventors: Jianshi Tao, Mandana Sassanfar, Paul L. Gallant, Xiaoyu Shen, Anthony S. Avruch, Russell V. Yu, Shamila Nair
  • Patent number: 5871987
    Abstract: The present invention relates to isolated and/or recombinant nucleic acids which encode Candida tyrosyl-tRNA synthetases, portions thereof, or fusion proteins comprising a Candida tyrosyl-tRNA synthetase or portion thereof. Also disclosed are constructs comprising the nucleic acids of the present invention, host cells comprising a recombinant nucleic acid or construct, and methods of producing a Candida tyrosyl-tRNA synthetase, portion thereof, or fusion protein comprising same. Also described are tester strains, which are cells engineered to rely on the function of a Candida tyrosyl-tRNA synthetase or functional fragment thereof encoded by an introduced cloned gene, and which can be used in a method of detecting an inhibitor of Candida tyrosyl-tRNA synthetase function.
    Type: Grant
    Filed: November 1, 1996
    Date of Patent: February 16, 1999
    Assignee: Cubist Pharmaceuticals, Inc.
    Inventors: Mandana Sassanfar, Paul L. Gallant, Xiaoyu Shen, Nianjun Tao, Jianshi Tao, Fariba Houman
  • Patent number: 5801013
    Abstract: Recombinant nucleic acids which encode aminoacyl-tRNA sythetases of helicobacter origin have been isolated. These nucleic acids can be used to make expression constructs and transformed host cells for the production of helicobacter aminoacyl-tRNA synthetases. They can also be used in the further isolation of nucleic acids related by DNA sequence similarities, which also encode helicobacter aminoacyl-tRNA synthetases, or portions thereof. A further embodiment of the invention is antisense nucleic acid which can hybridize to the nucleic acid which encodes the aminoacyl-tRNA synthetase of helicobacter. The invention also relates to isolated and/or recombinant helicobacter aminoacyl-tRNA synthetases. Antibodies which bind to these enzymes can be made and can be used in the purification and study of the enzymes.
    Type: Grant
    Filed: May 26, 1995
    Date of Patent: September 1, 1998
    Assignee: Cubist Pharmaceuticals, Inc.
    Inventors: Jianshi Tao, Yan Qiu, Fariba Houman, Xiaoyu Shen, Paul R. Schimmel